<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5545">
  <stage>Registered</stage>
  <submitdate>16/11/2009</submitdate>
  <approvaldate>16/11/2009</approvaldate>
  <nctid>NCT01015235</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy Study of KAI-1678 to Treat Subjects With Postoperative Pain</studytitle>
    <scientifictitle>A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion for the Treatment of Postoperative Pain</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>KAI-1678-002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pain, Postoperative</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Placebo
Treatment: drugs - KAI-1678
Treatment: drugs - Ketorolac Tromethamine

Placebo Comparator: Arm 1: Placebo - Placebo

Active Comparator: A2: KAI-1678 - Test Drug

Active Comparator: A3: Ketorolac - Active Comparator


Treatment: drugs: Placebo
Subcutaneous infusion-once over 4 hours

Treatment: drugs: KAI-1678
Subcutaneous infusion-once over 4 hours

Treatment: drugs: Ketorolac Tromethamine
Active comparator, IV infusion, once

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The effect of KAI-1678 on summed pain intensity difference over 4 hours (SPID 4).</outcome>
      <timepoint>Post operative Day 1</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The effect of KAI-1678 on total pain relief over 4 hours (TOTPAR 4)</outcome>
      <timepoint>Post operative Day 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The effect of KAI-1678 on pain intensity difference (PID) at 4 hours</outcome>
      <timepoint>Post-operative Day 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The effect of KAI-1678 on total quality analgesia</outcome>
      <timepoint>Post-operative Day 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The effect of KAI-1678 on time to meaningful pain relief</outcome>
      <timepoint>Post-operative Day 1</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  American Society of Anesthesiologist (ASA) classification 1, 2, or 3

          -  total hip or total knee replacement

          -  pain on postoperative Day 1 at least 40 mm on 0-100 mm visual analog scale (VAS)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  presence of contraindications to nonsteroidal anti-inflammatory (NSAID) treatment

          -  recent history of angina or myocardial infarction (MI)

          -  clinically significant abnormality on laboratory tests or electrocardiogram (ECG)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>90</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>KAI Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Trident Clinical Research Pty Ltd</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether KAI-1678 is effective in the treatment of
      postoperative pain following total hip or total knee replacement.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01015235</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gregory Bell, MD</name>
      <address>KAI Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>